Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma
Liping Song, … , Richard Sposto, Leonid S. Metelitsa
Liping Song, … , Richard Sposto, Leonid S. Metelitsa
Published September 4, 2007
Citation Information: J Clin Invest. 2007;117(9):2702-2712. https://doi.org/10.1172/JCI30751.
View: Text | PDF
Research Article Oncology

Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma

  • Text
  • PDF
Abstract

Vα24-invariant natural killer T (NKT) cells are potentially important for antitumor immunity. We and others have previously demonstrated positive associations between NKT cell presence in primary tumors and long-term survival in distinct human cancers. However, the mechanism by which aggressive tumors avoid infiltration with NKT and other T cells remains poorly understood. Here, we report that the v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN), the hallmark of aggressive neuroblastoma, repressed expression of monocyte chemoattractant protein–1/CC chemokine ligand 2 (MCP-1/CCL2), a chemokine required for NKT cell chemoattraction. MYCN knockdown in MYCN-amplified neuroblastoma cell lines restored CCL2 production and NKT cell chemoattraction. Unlike other oncogenes, MYCN repressed chemokine expression in a STAT3-independent manner, requiring an E-box element in the CCL2 promoter to mediate transcriptional repression. MYCN overexpression in neuroblastoma xenografts in NOD/SCID mice severely inhibited their ability to attract human NKT cells, T cells, and monocytes. Patients with MYCN-amplified neuroblastoma metastatic to bone marrow had 4-fold fewer NKT cells in their bone marrow than did their nonamplified counterparts, indicating that the MYCN-mediated immune escape mechanism, which we believe to be novel, is operative in metastatic cancer and should be considered in tumor immunobiology and for the development of new therapeutic strategies.

Authors

Liping Song, Tasnim Ara, Hong-Wei Wu, Chan-Wook Woo, C. Patrick Reynolds, Robert C. Seeger, Yves A. DeClerck, Carol J. Thiele, Richard Sposto, Leonid S. Metelitsa

×

Figure 4

MYCN directly binds CCL2 promoter.

Options: View larger image (or click on image) Download as PowerPoint
MYCN directly binds CCL2 promoter.
               
(A) CCL2 promoter cDN...
(A) CCL2 promoter cDNA constructs with (2.8 kb) and without (2.6 kb) E-box site were fused with a Firefly luciferase cDNA. A pGL3 plasmid containing only Firefly luciferase cDNA was used as a negative control. CHLA-255 or CHLA-255/MYCN cells were transiently cotransfected with the indicated constructs and pRLSV40 plasmid containing Renilla luciferase cDNA as an internal control. The activity of CCL2 promoter was detected in a dual-luciferase assay and expressed as a ratio of Firefly to Renilla luciferase luminescence intensity. (B) Nuclear extract from neuroblastoma cells was analyzed by EMSA with biotinylated E-box probe from CCL2 promoter. Lane 1, free probe; lane 2, nonbiotin (cold) probe plus probe plus CHLA-255/MYCN; lane 3, probe plus CHLA-255/vector; lane 4, probe plus CHLA-255/MYCN; lane 5, probe plus CHLA-255/MYCN plus anti-MYCN mAb; lane 6, probe plus CHLA-255/MYCN plus IgG control. Data are representative of 6 experiments. (C) Nuclear extract from CHLA-255/MYCN was analyzed by EMSA with E-box probe as above (positive control) or with INR probes. Lane 1, free E-box probe; lane 2, E-box probe plus CHLA-255/MYCN; lanes 3, 5, and 7, free probes for INR-1, INR-2, and INR-3, respectively; lanes 4, 6, and 8, CHLA-255/MYCN plus probes for INR-1, INR-2, and INR-3, respectively. Data are representative of 3 experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts